You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

Article metrics

Article menu

Download PDFPDF

XML
Psoriatic arthritis
Original research
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

 

Online download statistics by month:

Online download statistics by month: July 2021 to March 2024

AbstractFullPdf
Jul 202143433
Aug 2021557554264
Sep 202119719690
Oct 202115214494
Nov 202110310076
Dec 2021878254
Jan 20221009966
Feb 20221029941
Mar 202212112363
Apr 202214715374
May 202215315969
Jun 202212212339
Jul 202215715475
Aug 202212712950
Sep 202211912541
Oct 202211111242
Nov 2022938340
Dec 2022706739
Jan 20231009828
Feb 20231019731
Mar 202311410858
Apr 2023716639
May 2023868540
Jun 2023878032
Jul 202310610245
Aug 2023807842
Sep 202310210134
Oct 202313513175
Nov 20231039961
Dec 202311011154
Jan 202411710854
Feb 202412111755
Mar 2024838253
Total407740081921